LIU Yuxin,WEN Xiaotong,DUAN Fengran,et al.Analysis of influential factors for purchasing quantity changes in the procurement varieties of the first batch of drug centralized procurement[J].ZHONGGUO YAOFANG,2024,35(06):641-646.
LIU Yuxin,WEN Xiaotong,DUAN Fengran,et al.Analysis of influential factors for purchasing quantity changes in the procurement varieties of the first batch of drug centralized procurement[J].ZHONGGUO YAOFANG,2024,35(06):641-646. DOI: 10.6039/j.issn.1001-0408.2024.06.01.
Analysis of influential factors for purchasing quantity changes in the procurement varieties of the first batch of drug centralized procurement
To investigate the factors influencing the changes in purchasing quantity in the procurement varieties of the first batch of volume-based drug centralized procurement (hereinafter referred to as centralized procurement).
METHODS
2
Using 25 procurement varieties of the “4+7” policy as research objects, the changes in purchasing quantity of procurement varieties were analyzed before and after the implementation of the “4+7” pilot, renewal and expansion policies. The influential factors were determined from the three levels of drugs, medical institutions and regions; and the multiple linear regression model was used to analyze the influential factors for the changes in the purchasing quantity of procurement varieties.
RESULTS
2
Before and after the implementation of the “4+7” pilot, renewal and expansion policies, the purchasing quantity increased by 52.1, -0.2, 85.8 ten thousand DDDs on average, compared with base period. During pilot, renewal and expansion period, DDDc decrease in procurement varieties was positively correlated with the increase in purchasing quantity (
P
<0.01). During the pilot and renewal period, the number of absolutely alternative varieties was positively correlated with the increase in purchasing quantity (
P
<0.1). During the pilot and expansion period, the number of alternative varieties to a certain extent was negatively correlated with the increase in purchasing quantity (
P
<0.05). During the renewal period, the increment of purchasing quantity in tertiary hospitals was smaller than that of primary medical institutions (
P
<0.05).
CONCLUSIONS
2
There is a relationship between the decline of DDDc and the changes in the purchasing quantity, that is, the more the drug price dropped, the more the purchasing quantity increased. The number of alternative varieties for centralized procurement will affect the changes in their purchasing quantity, but it is not always stable. With the implementation of the policy, the volume of primary medical institutions gradually exceeds that of tertiary institutions, indicating that the consumption of centralized purchased varieties is transferred to the primary medical institutions, and centralized procurement has promoted the implementation of the hierarchical diagnosis and treatment system.
SEIDMAN G,ATUN R. Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals,vaccines or health pro-ducts? A systematic review of evidence from low-income and middle-income countries[J]. BMJ Glob Health,2017,2(2):e000243.
YANG Y,CHEN L,KE X F,et al. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen,2018-2019:an interrupted time-series analysis[J]. BMC Health Serv Res,2021,21(1):668.
YANG Y,TONG R W,YIN S C,et al. The impact of “4 + 7” volume-based drug procurement on the volume,expenditures,and daily costs of antihypertensive drugs in Shenzhen,China:an interrupted time series analysis[J]. BMC Health Serv Res,2021,21(1):1275.
YAN J J,ZHAO Y W,YAN B,et al. Study on the implementation effect of drug purchase policy based on discontinuous time series[J]. Price Theory Pract,2022(12):56-60,195.
CHEN M F,XIE J P,WANG B,et al. Study on the dif-ference of implementation effect of purchasing policy with quantity in hospitals at all levels in Changzhou[J]. Chin Health Resour,2022,25(6):765-769,779.
XU Y,SONG J,CHEN M X. Policy effect and enlightenment of Shanghai medical insurance drug purchase with quantity[J]. Chin Health Resour,2022,25(3):278-282.
WEN X T,WANG Y,DUAN F R,et al. The impact of national centralized drug procurement on the drug procurement in different levels of public medical institutions[J]. China Health Insur,2023(3):32-40.
Aimeda Medical Consulting. The first to fifth batches of substitute drugs for domestically purchased varieties have been released[EB/OL].(2021-12-12)[2023-06-22].https://xueqiu.com/9517383519/206283730https://xueqiu.com/9517383519/206283730.
JIANG S,GE W H,MU G L,et al. Analysis of the implementation effect of the national volume-based procurement in a public hospital[J]. Chin Hosp Manag,2022,42(7):70-73.
ZHAO J,LI W,WANG G J. Effect evaluation of national drug centralized volume-based procurement in a public hospital from the perspective of value-based healthcare[J]. China Pharm,2021,32(19):2410-2414.
YANG Z F,YANG L,QIU L,et al. Effect analysis of national drug procurement with quantity in a secondary hospital in Songjiang district of Shanghai[J]. J China Prescr Drug,2022,20(6):32-35.
LI C X,YANG Z Y,LIU Y,et al. Utilization analysis of “4+7” procurement policy with quantity on using of lipid-regulating drugs in the Affiliated Hospital of Chengdu University[J]. Drugs Clin,2022,37(1):179-186.
GAO J J,WU X F,XU Y,et al. Influence of centralized drug purchase on the price index of hypertension-related drugs in a hospital[J]. Strait Pharm J,2021,33(7):214-217.
WEN X T,ZHAO Q L,LIU Y X,et al. Comparison of the contribution rate of different levels of public medical institutions to the changes in centralized drug procurement vo-lume[J].China Health Insur,2023(11):122-128.
SUN Y,ZHU Z,YANG L. Analysis on influencing factors of price reduction in national volume-based drug procurement[J]. Chin J Health Policy,2022,15(2):54-59.